Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Anticancer evidence for zoledronic acid across the cancer continuum
Luis Costa
, Peter Harper
, Robert E. Coleman
, Allan Lipton
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Research output
:
Contribution to journal
›
Review article
›
peer-review
29
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Anticancer evidence for zoledronic acid across the cancer continuum'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Zoledronic Acid
100%
Anticancer
100%
Anticancer Activity
42%
Clinical Trials
28%
Skeletal-related Events
14%
Clinically Significant
14%
Survival Benefit
14%
Circulating Tumor Cells
14%
Recurrent Disease
14%
Tumor Size
14%
Disease-free Survival
14%
Cancer Types
14%
Early Breast Cancer
14%
Invasive Tumors
14%
Patients with Advanced Cancer
14%
Patients with Cancer
14%
Disseminated Tumor Cells
14%
Medicine and Dentistry
Malignant Neoplasm
100%
Zoledronic Acid
100%
Antineoplastic Activity
42%
Clinical Trial
28%
Neoplasm
14%
Breast Cancer
14%
Metastatic Carcinoma
14%
Advanced Cancer
14%
Retrospective Study
14%
Recurrent Disease
14%
Circulating Tumor Cell
14%
Disease Free Survival
14%
Cancer Types
14%
Biochemistry, Genetics and Molecular Biology
Anticancer
100%
Antineoplastic Activity
100%
Clinical Trial
66%
Tumor Volume
33%
Retrospective Study
33%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Zoledronic Acid
100%
Clinical Trial
28%
Breast Cancer
14%
Metastasis
14%
Neoplasm
14%
Advanced Cancer
14%
Retrospective Study
14%
Recurrent Disease
14%
Disease Free Survival
14%